| Roche Pharma (Schweiz) AG - Enspryng 120 mg, Injektionslösung zur subkutanen Anwendung |
| 67617 | | 01 | | Enspryng 120 mg | | Injektionslösung zur subkutanen Anwendung | | L04AC19 | | Satralizumab | | 13.07.2020 | | |
|
| Composition |
| satralizumabum 120 mg, histidinum, acidum asparticum, argininum, poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 1 ml. |
| Packungsbestandteile |
| Injektionslösung zur subkutanen Anwendung | | | | | | | | Active Agent | Dose |
|---|
| Satralizumabum | 120 mg/ml |
| | BAG: Active Agent | Dose |
|---|
| Satralizumabum | 120 mg |
| | | | Inactive agents | Dose |
|---|
| Aspartic Acid | | | Arginine | | | Histidine | | | Poloxamer | 188 |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | 6682.56 | 7164.10 | A | SL | Yes |
|
